top of page

Your  R&D

Neuro-Sys is a research-intensive and innovative organization specializing in pharmacology and in advanced in vitro and in vivo models of neurodegenerative diseases, mode of action research, and drug development in the CNS and PNS fields.

Award winning CRO


of the year 2023

Global Health Pharma, UK

Oct. 2023


Experts in
preclinical modelling



 EVENT  June 3-6, 2024, San Diego, CA

Neuro-Sys will attend the Bio International Convention.

Our CEO, CSO and VP of Business Development invite you to the partnering meetings and explore collaborative opportunities with Neuro-Sys!

> More


 EVENT  May 21-23, 2024, Boston, MA

Neuro-Sys will sponsor and exhibit at the 3rd Annual ALS Drug Development Summit

> More


 EVENT  April 23-25, 2024, Boston, MA

Neuro-Sys will sponsor and exhibit at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit

Our CSO will be giving a talk on: "Parkinson’s disease: alpha-synuclein’s mechanisms of cell death in vitro and in vivo evidences"

> More

Cortex AI3_2.png

 INNOVATION  January 18, 2024

CORTEX AI project

Thanks to the innovative integration of artificial intelligence into Neuro-Sys processes, CORTEX AI promises to revolutionize neuroscientific studies with unmatched precision, efficiency, and speed. This advanced technology enables complex data analysis for a better understanding of the mechanisms of action in neurodegenerative diseases, offering new perspectives and solutions in this critical field.

> More


 POSTERS  November 15, 2023

Poster presentation @SFN 2023

"Toxicity of amyloid beta oligomers involves chronic hyperphosphorylation of Tau: evidence from in vitro and in vivo models."

Poster # N6P45


 POSTERS  November 14, 2023

Poster presentation @SFN 2023

"SOD1G93A mutation connects mitochondrial dysfunctions, neuromuscular junction disruption and increased sensitivity to glutamatergic stress in in vitro models of ALS."

Poster # N6P44

Jul23558_Neuro-Sys_GHP_Healthcare & Pharma_2023_TD-TP07C_Trophy x1.png

 AWARDS  October, 2023

We are proud to announce that Neuro-Sys has been awarded

"Best CRO of the Year 2023" for Europe by Global Health & Pharma (UK).

This is a tribute to the quality work of our teams and the excellence of our scientific integrity that we offer to our clients and partners every day.

> More


 EVENT  October 9-10, 2023, London, UK

Neuro-Sys will sponsor and exhibit at the 6th Annual Neuroscience R&D Conference


Our CSO will be giving a talk on:

"Parkinson’s disease: alpha-synuclein toxicity and spreading, in vitro and in vivo models."

design Book

 PUBLICATIONS  August 30, 2022

Alpha-Synuclein: The Spark That Flames Dopaminergic Neurons, In Vitro and In Vivo Evidence

Alexandre Henriques, Laura Rouvière, Elodie Giorla, Clémence Farrugia, Bilal El Waly, Philippe Poindron and Noelle Callizot

> More


 PUBLICATIONS  August 09, 2022

NX210c Peptide Promotes Glutamatergic Receptor-Mediated Synaptic Transmission and Signaling in the Mouse Central Nervous System

Sighild Lemarchant, Mélissa Sourioux, Juliette Le Douce, Alexandre Henriques, Noelle Callizot, Sandrine Hugues, Mélissa Farinelli and Yann Godfrin

> More


 POSTERS  August 01, 2022

Poster presentation @AAIC 2022

"Neuroinflammation and microglial activation in Alzheimer’s Disease: in vitro and in vivo models of study."

Poster # N6P42


 POSTERS  July 13, 2022

Poster presentation @FENS 2022

"New in vivo model of Parkinson’s disease involving combined toxicity of alpha-synuclein oligomers and protofibrils, and chronic inhibition of GBA."

Poster # N6P41


 POSTERS  July 12, 2022

Poster presentation @FENS 2022

"Loss of GBA activity exacerbate the toxicity of alpha-synuclein oligomers and protofibrils in an in vitro model of Parkinson’s disease."

Poster # N6P40


 AWARDS  August 29, 2021


Neuro-Sys inc. elected 2021 World's Best CRO of the year by Corporate Live Wire (UK).

We are very proud of this distinction, which congratulates several years of preclinical scientific excellence, the continuous efforts of our team of experts and the significant investments undertaken.

> More

design Book

 PUBLICATIONS  August 30, 2021

NSP01, a green extract of Huperzia serrata with neuroprotective effects related to synergistic action of Huperzine A and polyphenols

Noelle Callizot, Maria-Letizia Campanari, Laura Rouvière, Guillaume Jacquemot, Alexandre Henriques, Elnur Garayev and Philippe Poindron

> More

design Book

 PUBLICATIONS  August 19, 2021

AZP2006, a new promising treatment for Alzheimer’s and related diseases

N Callizot, C Estrella, S Burlet, A Henriques, C Brantis, M Barrier, M L Campanari, P Verwaerde

> More


 PLATFORMS  March 8, 2021


The histology department is strengthened with the reinforcement of the team and the investment in the latest equipment.

> More

bottom of page